Overview

Telerehabilitation Alzheimer's Disease Feasibility (TADF)

Status:
Not yet recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a pilot RCT with equal arms: experimental arm and (wait list) control arm. All participants will be in the early stage of Alzheimer's disease and on stable medication. They will all continue with this medication for their 6 months participation. Experimental group will add weekly training on the experimental device, 5 days a week for 12 weeks. Training will involve therapeutic games aimed primarily at the memory cognitive domain. All participants will receive weekly calls from clinical coordinator and report on medication and overall health. Caregivers will also be enrolled so they support the trials.
Phase:
N/A
Details
Lead Sponsor:
Bright Cloud International Corp
Collaborators:
National Institute on Aging (NIA)
Rutgers, The State University of New Jersey
Treatments:
Donepezil